Post #ASH21 by the IACH: CAR-T cells

Chronic lymphocytic leukemia at ASH21: What's new?Подробнее

CAR-T cell therapy for adult ALLПодробнее

Cellular therapy - a post ASH 2020 summaryПодробнее

Pre- and post-CAR T-cell therapy costsПодробнее

Myeloma news live from #ASH21 by the IACH - Part 2Подробнее

Cytopenias post-CAR T-cell therapyПодробнее

CAR-T cells in multiple myelomaПодробнее

Post #ASH21 by the IACH: Hematopoietic Cell TransplantationПодробнее

IACH 2019: CAR T cell therapy - How to set up a clinical unitПодробнее

Armored CAR T cells in Multiple MyelomaПодробнее

CAR-T Cell TherapyПодробнее

Barriers to using CAR T-cells in solid tumors and strategies to overcome themПодробнее

CD19 CAR T Cell Therapy for Pediatric ALL: The Seattle Children’s ExperienceПодробнее

The Science of CAR T cellsПодробнее

CAR-T Post-Infusion Care, Financial Considerations, and Data ManagementПодробнее

What is CAR T-Cell Therapy?Подробнее

What is CAR T-Cell Therapy?Подробнее

CAR T-Cell Therapy: ASCO’s 2018 Advance of the YearПодробнее

Gut microbiome correlates of response and toxicity following anti CD19 CAR T cell therapyПодробнее